5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It was developed at the University of Texas at Austin and UT Medical Branch by Stanley Watowich, Harshini Neelakantan, and colleagues. Preclinical mouse studies report reductions in fat mass, adipocyte volume, and body weight on high-fat diet, plus improvements in muscle function in aged mice. No human pharmacokinetic, safety, or efficacy data has been published.

The molecule is a quinolinium derivative: a bicyclic aromatic nitrogen heterocycle with a methyl group on the ring nitrogen and a single amino substituent at the 5-position. Molecular weight is approximately 159 g/mol. It is water-soluble and membrane-permeable, which is what made it useful as a research tool. Earlier NNMT inhibitors (1,2,4,8-tetramethylquinolinium and related analogs) inhibited the enzyme well in test tubes but failed to cross cell membranes in living tissue.

Origins and Development

The NNMT-obesity connection started with Kraus et al. in Nature, 2014. They used antisense oligonucleotide (ASO) knockdown of NNMT in mice on a high-fat diet and showed reduced body weight gain, reduced fat mass, improved glucose tolerance, lower serum insulin, and reduced hepatic triglycerides. This was a genetic approach, not a drug. It established the target.

The pharmacological proof-of-concept came from Neelakantan et al., Biochemical Pharmacology, 2018. The group screened a series of quinolinium analogs and identified 5-Amino-1MQ (their "Compound 9") as the lead. It met four criteria: selective NNMT inhibition, sub-micromolar potency in cell-free assays, membrane permeability (high in PAMPA and Caco-2 assays), and oral activity in mice.

The original mouse study used systemic administration in diet-induced obese mice over 11 days. Results: reduced body weight (despite no change in food intake), reduced white adipose tissue mass, reduced adipocyte volume by approximately 30 to 40 percent, and reduced plasma total cholesterol. In differentiated 3T3-L1 adipocyte culture, 30 μM of 5-Amino-1MQ reduced intracellular 1-methylnicotinamide, increased intracellular NAD+, and suppressed lipogenesis.

Subsequent Studies

Sampson, Dimet, Neelakantan and colleagues, Scientific Reports 2021, combined 5-Amino-1MQ with a lean-diet substitution in diet-induced obese mice (n=6-8 per group). The combination significantly reduced body weight and fat mass (both p < 0.0001) and lowered hepatic lipid content compared with either intervention alone.

Dimet-Wiley et al., Scientific Reports 2024, tested 5-Amino-1MQ in aged mice (24 months). NNMT inhibition combined with progressive weighted-wheel running (PoWeR) improved grip strength to a greater degree than exercise alone. Daily running distances increased and remained elevated. The compound alleviated the muscle-recovery deficit that aged mice typically show after vigorous exercise. The paper described the compound as "mimicking and boosting" exercise-mediated improvements in muscle function.

A 2025 paper from related collaborators reported enhanced myofiber regeneration after injury in aged mice through rejuvenation of muscle stem cell (muSC) activity.

The pattern is consistent: NNMT inhibition in mice produces fat reduction, muscle benefit, and metabolic improvement. The translation to humans has not been attempted in any published trial.

Regulatory and Sport Status

5-Amino-1MQ has no marketing approval in any jurisdiction. It is sold as a research chemical by Cayman Chemical, MedChemExpress, and similar suppliers to research laboratories, and as oral capsules or injectable powder by research-peptide vendors to consumers. None of these products are FDA-approved or pharmaceutical-grade.

The WADA status is currently unresolved. 5-Amino-1MQ is not explicitly named on the 2026 WADA Prohibited List, and unlike SLU-PP-332, no doping-control metabolite-identification paper has been published. Section S4 (Hormones and Metabolic Modulators) and its catch-all clause for substances that mimic metabolic adaptation could be applied. The compound's documented effect of reducing body weight and fat mass in mice without changing food intake or activity is precisely the kind of profile that anti-doping bodies treat as in-scope. Athletes subject to testing should apply caution.

No commercial pharmaceutical sponsor has filed an IND application for 5-Amino-1MQ as of public records.

NNMT (nicotinamide N-methyltransferase) is a cytosolic enzyme that catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor. The reaction produces 1-methylnicotinamide (MNA, also called 1-MNA) and S-adenosylhomocysteine (SAH). The reaction has two metabolically important consequences:

1. Depletes nicotinamide, the salvage-pathway substrate for NAD+ synthesis. Methylated nicotinamide cannot be recycled back into NAD+.
2. Depletes SAM, the universal methyl donor used in hundreds of reactions including DNA and histone methylation.

In adipose tissue from obese animals and obese humans, NNMT expression is markedly elevated. In differentiated 3T3-L1 adipocytes, Neelakantan and colleagues measured NNMT protein expression approximately 37-fold higher than in pre-adipocytes (p < 0.0001) and 1-MNA levels approximately 7.5-fold higher (p < 0.05). The Kraus 2014 work and several subsequent studies linked this NNMT hyperactivity to reduced energy expenditure, suppressed mitochondrial activity, and increased fat storage.

5-Amino-1MQ binds the active site of NNMT and prevents nicotinamide methylation. The compound is described as NAM-competitive: it competes with nicotinamide (NAM) for the substrate binding site rather than acting as a SAM-competitive or allosteric inhibitor. This selectivity reduces the risk of off-target methyltransferase inhibition. At concentrations that significantly inhibit NNMT, 5-Amino-1MQ largely leaves other cellular methyltransferases (DNMT, HMT, COMT) alone.

Downstream consequences of NNMT inhibition in adipocytes:

• NAD+ rises by approximately 1.2 to 1.6 fold (cell culture data)
• SAM is preserved, supporting methylation reactions throughout the cell
• AMPK signaling is activated (mechanism partially mediated by elevated NAD+ supporting sirtuin function)
• Lipogenesis is suppressed at the gene-expression level
• Mitochondrial function increases, with associated rises in fatty acid oxidation
• GLUT4 expression increases in some studies, supporting glucose uptake

These effects converge on a phenotype of smaller, more metabolically active adipocytes.

Pharmacokinetics: in mice, oral and intraperitoneal dosing both produce plasma exposure sufficient for in vivo effect over multi-day treatment. The compound is renally cleared. Human pharmacokinetics have not been measured in any published study.

Mouse data:

• Reduced body weight gain on high-fat diet without change in food intake (Neelakantan 2018)
• 30 to 40 percent reduction in adipocyte size, both subcutaneous and visceral (Neelakantan 2018)
• Improved glucose tolerance and reduced fasting insulin (Kraus 2014 ASO and Neelakantan 2018 small-molecule)
• Reduced hepatic triglycerides (Neelakantan 2018, Sampson 2021)
• Improved grip strength in aged mice, greater effect than exercise alone (Dimet-Wiley 2024)
• Sustained running distance over weeks of training (Dimet-Wiley 2024)
• Enhanced myofiber regeneration after injury (2025 follow-up)

Cell-culture data:

• NAD+ rise 1.2 to 1.6 fold in adipocytes
• 1-MNA decrease, confirming target engagement
• Suppression of lipogenesis genes
• No cytotoxicity at 10 μM in 3T3-L1 cells over 24 hours

Human data: zero published controlled studies.

User reports from research-chemical communities at oral doses in the 50-150 mg range describe subjective fat loss, particularly abdominal, often co-administered with caloric restriction or GLP-1 receptor agonists. None of these reports is from controlled trial. The bioavailability and target engagement at these doses in humans is not established.

The mouse fat-loss effect occurred without exercise or change in food intake. This is mechanistically interesting because it suggests an exercise- and appetite-independent path to fat-mass reduction. Whether the same mechanism is active at the doses being used by humans is unknown.

Published mouse doses for the Neelakantan 2018 pivotal study used systemic administration over 11 days. Specific doses were 5 mg/kg and 10 mg/kg intraperitoneal. Later studies used 5 to 20 mg/kg per day across 4 to 12 week durations.

For a 70 kg human, naïve allometric scaling from a 25 g mouse using standard body-surface-area conversion (mouse Km factor 3, human Km factor 37) translates a 10 mg/kg mouse dose to approximately 0.8 mg/kg in humans, or 56 mg per day. This calculation is not a recommended dose. It is a heuristic showing where the published mouse exposure sits relative to human-equivalent dose estimates.

Off-label community protocols that circulate in research-chemical communities use oral doses in the range of 50 to 150 mg per day, typically once daily in the morning, often cycled for 4 to 12 weeks. These dose ranges sit close to the allometric-scaled estimate but have not been validated against any human pharmacokinetic data. Sublingual and subcutaneous routes are also marketed; supporting evidence for either route in humans is sparse.

No standardized human dosing protocol exists for 5-Amino-1MQ. All circulating protocols are extrapolations from preclinical work without bridging human safety or pharmacokinetic data.

Mouse safety data in the Neelakantan 2018 and follow-up studies showed no significant adverse effects at the doses used. Body weight in non-obese controls was unchanged. No mortality. No abnormal organ pathology in the studied tissues. The compound did not affect food intake or behavior.

Cell culture cytotoxicity at 10 μM in 3T3-L1 cells over 24 hours showed no impact on viability.

Human safety data: none.

Theoretical concerns:

• Off-target methyltransferase effects: NAM-competitive binding gives selectivity for NNMT, but high-dose chronic exposure has not been tested for effects on DNA methyltransferases (DNMT1, DNMT3A/B), histone methyltransferases, or COMT (catechol-O-methyltransferase, which metabolizes dopamine, epinephrine, and estradiol). Nonselective methyltransferase inhibition could theoretically cause epigenetic and neurotransmitter effects.
• Methyl donor balance: NNMT inhibition raises cellular SAM, which is metabolically favorable, but extreme elevation could shift methylation patterns in DNA and histones in ways that have not been characterized.
• Long-term effects: the longest preclinical studies in mice are approximately 12 weeks. Six-month, 12-month, or lifetime exposure has not been studied. NNMT may have physiological roles in tissues other than adipose that are currently underappreciated.
• Adipocyte rebound: stopping NNMT inhibition allows the enzyme to resume normal activity. Whether body weight rebounds after cessation, as with most weight-loss interventions, has not been systematically studied.
• Drug interactions: not characterized. Particular caution is appropriate with GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide), which are often co-used in off-label community protocols. The combination has not been studied in any animal model.
• Cancer biology: NNMT is overexpressed in several tumor types (renal cell carcinoma, pancreatic, ovarian, colorectal) and is investigated as both a marker and a target in oncology. Whether systemic NNMT inhibition affects tumor biology favorably or unfavorably is unresolved.

5-Amino-1MQ is the central NNMT-inhibitor compound in the research-chemical longevity ecosystem. Its closest functional analog is JBSNF-000088, another NNMT inhibitor in earlier preclinical development. JBSNF-000088 is methylated by NNMT itself (a suicide-substrate strategy), unlike the NAM-competitive mechanism of 5-Amino-1MQ.

The pairing with NAD+ precursors (NMN, NR) addresses two ends of the same pathway: NMN and NR add salvage-pathway substrate, while 5-Amino-1MQ prevents existing substrate from being methylated away. Mechanistically reasonable, untested as a combination in humans.

The pairing with SLU-PP-332 combines a substrate-preservation mechanism (5-Amino-1MQ raising NAD+ and SAM) with a transcriptional activation mechanism (ERR agonism activating mitochondrial biogenesis genes). Theoretically synergistic. Empirically untested.

The pairing with GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) is widely used in off-label community protocols, with the argument that 5-Amino-1MQ targets adipocyte metabolism directly while GLP-1 agonists work on appetite, gastric emptying, and central energy balance. No controlled animal study or human trial has tested this combination.

The pairing with caloric restriction or fasting is mechanistically reasonable: both lower NNMT activity indirectly through metabolic state changes. The Sampson 2021 paper combined 5-Amino-1MQ with lean-diet substitution and reported additive effects in mice.

The pairing with exercise is supported by the Dimet-Wiley 2024 mouse data, which showed that combining the compound with progressive resistance training produced greater muscle improvements than either alone. The same study suggested 5-Amino-1MQ reduced the recovery deficit that aged mice show after vigorous training. Whether the same effect occurs in aged humans is unknown.

The pairing 5-Amino-1MQ should be approached carefully with is any active cancer treatment. NNMT has tumor-biology implications in multiple malignancies. Patients on chemotherapy, particularly for cancers where NNMT is a known marker, should not add this compound without oncologist input.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.